Skip Navigation

JNCI Journal of the National Cancer Institute 2000 92(19):1549-1551; doi:10.1093/jnci/92.19.1549
© 2000 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Mendelsohn, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mendelsohn, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 92, No. 19, 1549-1551, October 4, 2000
© 2000 Oxford University Press

EDITORIAL

Use of an Antibody to Target Geldanamycin

John Mendelsohn

Correspondence to: John Mendelsohn, M.D., The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030 (e-mail: jmendelsohn@mdanderson.org).

The promise of antibodies as mediators of effective targeted anticancer therapy is beginning to be fulfilled. In the past few years, two monoclonal antibodies (MAbs) have been approved for selective use by the U.S. Food and Drug Administration (FDA) (Rockville, MD) and incorporated into standard therapy, resulting in improved clinical responses and prolongation of life. The most dramatic clinical response has been to rituximab, which is directed against the CD-20 antigen on lymphoma cells (1). Herceptin against the HER2 receptor has proved to be effective in combination with chemotherapy for a subpopulation of breast cancer patients whose malignant cells express high levels of this receptor (2).

Since the discovery of methods for producing large quantities of MAbs by Kohler and Milstein in 1975 (3), investigators have explored the following three ways of using MAbs to treat cancer: 1) as mediators of immune cytotoxicity through . . . [Full Text of this Article]

NOTES

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?